P2RY12 and atrial fibrillation: Recent randomized controlled trials demonstrated favorable outcomes of patients with AF and coronary artery disease treated by dual antithrombotic therapy (DAT) including P2Y12 inhibitors and direct OACs (DOACs) [59,60,61,62].